Combioxin is a biotechnology company focused on developing innovative treatments for severe infections, particularly through its lead product, CAL02. This novel anti-toxin agent is specifically designed to address severe community-acquired bacterial pneumonia by utilizing engineered liposomes. These liposomes work by neutralizing virulence effectors that contribute to organ failure and other serious complications associated with severe infections. The therapeutic approach of CAL02 represents a significant advancement in infection treatment, as it targets the underlying mechanisms of disease rather than merely the pathogens themselves. The drug has received both FDA Fast-Track and Qualified Infectious Disease Product (QIDP) designations, highlighting its potential importance in addressing critical health challenges.

Currently, CAL02 is undergoing a global Phase 2 clinical study, which aims to evaluate its efficacy and safety in treating severe pneumonia. The urgency of this research is underscored by the high incidence and mortality rates associated with pneumonia, which is a leading cause of hospitalization and death worldwide. With over 300 million cases reported annually and significant mortality rates, particularly among vulnerable populations, the development of CAL02 could provide a much-needed solution in the fight against severe infections. The collaboration with Eagle Pharmaceuticals for the commercial rights to CAL02 further emphasizes the potential impact of this innovative treatment in the healthcare landscape.

Switzerland

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance

Combioxin

Company Details